GSK, the UK’s second-biggest drugmaker, has unveiled a $2.2bn (£1.6bn) deal to acquire a Californian biotech company which is developing a drug to protect against severe food allergies, including allergies to nuts, milk and eggs.
It is the first large deal announced by GSK’s new chief executive, Luke Miels, who joined the London-based company in 2017 as chief commercial officer and took the reins from Emma Walmsley at the start of the year.
